Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
GSK
Marketing
AstraZeneca and Merck's Lynparza set to 'dominate' PARP market
AZ and Merck were the first to grab an FDA approval for Lynparza, and, despite growing competition, the drug is set to remain top in the PARP space.
Ben Adams
Apr 24, 2024 8:23am
Sanofi's Zantac settlement is worth $100M: Bloomberg
Apr 22, 2024 2:06pm
Top 20 pharma companies by 2023 revenue
Apr 15, 2024 3:00am
Pfizer plots new RSV filing with positive Abrysvo data in adults
Apr 9, 2024 6:45am
Sanofi agrees to resolve 4,000 Zantac claims in state courts
Apr 4, 2024 11:36am
GSK sets $35 out-of-pocket price cap for its inhalers in the US
Mar 21, 2024 11:45am